SRC (PP2), AKT and ERK/MEK (UO126) inhibitors provoked a clear decrease in the invasive and transendothelial migration capacity of scrambled melanoma and breast cancer transfectants, similar to those achieved by VE-cadherin-silenced counterparts. This evidence concerns the gene CDH5 and melanoma.